rss
J Med Genet 2008;45:29-31 doi:10.1136/jmg.2007.051177
  • Short report

Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells

  1. C Angelozzi,
  2. F Borgo,
  3. F D Tiziano,
  4. A Martella,
  5. G Neri,
  6. C Brahe
  1. Istituto di Genetica Medica, Universitè Cattolica S Cuore, Rome, Italy
  1. Dr C Brahe, Istituto di Genetica Medica, Universitè Cattolica, Largo Francesco Vito, 1, I-00168 Rome, Italy; cbrahe{at}rm.unicatt.it
  • Received 6 September 2007
  • Revised 6 September 2007
  • Accepted 13 September 2007
  • Published Online First 11 October 2007

Abstract

Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by homozygous absence of the survival motor neuron gene (SMN1). All patients have at least one, usually two to four copies of the related SMN2 gene which, however, produce insufficient levels of functional SMN protein due to the exclusion of exon 7 in the majority of SMN2 transcripts. Here, we show that salbutamol, a β2-adrenoceptor agonist, determines a rapid and significant increase in SMN2-full length mRNA and SMN protein in SMA fibroblasts, predominantly by promoting exon 7 inclusion in SMN2 transcripts. These data, together with previous clinical findings, provide a strong rationale to investigate further the clinical efficacy of salbutamol in SMA patients.

Footnotes

  • Competing interests: None declared.

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.